GLP-1 drugs may have a beneficial effect across many types of cancer

Key Points:

• Recent studies presented at the American Society of Clinical Oncology meeting indicate that GLP-1 drugs, commonly used for diabetes and weight loss, may reduce the risk of developing various cancers, slow disease progression, and improve survival rates.
• Research involving over 12,000 patients showed that GLP-1 use was linked to a 38% to 50% reduction in cancer metastasis, particularly in lung, breast, colorectal, and liver cancers, with benefits also observed in endometrial, bladder, prostate cancers, and blood cancers.
• GLP-1 medications appear to enhance outcomes for cancer patients receiving immunotherapies and are associated with better overall survival across multiple tumor types, including breast, prostate, colorectal, lung, liver, and kidney cancers.
• While these findings are promising, they are mainly based on observational studies, which cannot establish causation; randomized clinical trials are needed to confirm the anti-cancer benefits of GLP-1 drugs.
• The potential cancer-protective effects of GLP-1 drugs may stem from their anti-inflammatory and immune-modulating properties, rather than solely from weight loss, highlighting the need for further research into their mechanisms.